Abstract
To more accurately predict the malignancy of superficial esophageal cancer, this study examined the expression of epidermal growth factor (EGF) and its receptor (EGFR) using immunohistochemical methods on paraffin sections. The study included 36 cases of untreated superficial esophageal cancer, with 32 cases of advanced esophageal cancer as controls. In superficial cancers, EGF expression was significantly higher in cases with deeper invasion (sm3 vs. mm/sm2) and in those with lymphatic invasion. Patients with high EGF expression had significantly lower postoperative survival rates. Cases expressing both EGF and EGFR showed a significantly higher rate of lymphatic invasion and poorer postoperative survival. Notably, all nine cases of recurrence exhibited EGF expression. These findings suggest that EGF and EGFR are expressed from the early stages of esophageal cancer, and EGF, in particular, may serve as a critical indicator for predicting prognosis and recurrence in superficial esophageal carcinoma.
Introduction
Superficial esophageal cancer, while often considered treatable, presents a clinical challenge due to a high postoperative recurrence and mortality rate (30–40%)—significantly higher than early-stage gastric or colorectal cancers. Current clinical management relies heavily on pathological staging, such as the depth of tumor invasion. However, these morphological markers often fail to capture the underlying biological aggressiveness of the tumor. This study investigates whether molecular markers, specifically the EGF/EGFR signaling pathway, can provide a more precise prediction of patient outcomes.
Methods: Immunohistochemical Analysis
The researchers employed immunohistochemistry (IHC) on paraffin-embedded tissue sections to visualize protein expression. This technique uses specific antibodies to bind to EGF and EGFR, which are then highlighted by a chromogen (staining them brown).
A "positive" result was defined as protein expression in more than 51% of the tumor area. The study analyzed 36 superficial cases, 32 advanced cases, and 11 metastatic lymph nodes from patients treated between 1972 and 1992.
Key Findings
Early Expression and Tumor Depth
EGF and EGFR are not merely markers of advanced disease; they are present from the earliest stages of esophageal carcinoma. A significant correlation was found between the depth of invasion and EGF expression. While 0% of tumors confined to the mucous membrane were EGF-positive, 90% of tumors reaching the deepest submucosal layer (sm3) expressed the growth factor.
The Autocrine Loop and Aggressiveness
The co-expression of both EGF and its receptor (EGFR) was associated with the most aggressive tumor behavior. This "double positive" status likely indicates an autocrine loop where the tumor stimulates its own growth, leading to significantly higher rates of lymphatic invasion and poor survival.
Results and Prognostic Value
- Survival Impact: The 4-year survival rate for EGF-positive patients was 40.0%, compared to 100% for EGF-negative patients.
- Lymphatic Spread: EGF-positive tumors showed lymphatic invasion in 79.2% of cases, versus only 16.7% in EGF-negative cases.
- Recurrence: Remarkably, 100% of patients who experienced recurrence (9/9) had EGF-positive primary tumors.
Discussion
The results demonstrate that EGF expression is a fundamental driver of esophageal cancer progression from its inception. Interestingly, the rate of EGF expression did not differ significantly between superficial (58%) and advanced (59%) cancers, suggesting its role is established early.
While the sample size is relatively small (n=36 for superficial cases), the statistical significance of the findings is robust. Future clinical applications could include using EGF/EGFR testing on preoperative biopsies to identify high-risk patients who may require more aggressive surgical or adjuvant therapies despite having "superficial" lesions.
Summary updated